Literature DB >> 15125126

Weakness of extensor hallucis longus after removal of non-vascularised fibula as an autograft.

V U Shingade1, S M Jagtap, A B Ranade.   

Abstract

The upper three-quarters of the fibula is commonly used as a non-vascularised autograft. Subsequent to this isolated weakness of extensor hallucis longus may occur. We have studied 26 patients in whom the upper and middle thirds of the fibula had been harvested as a graft through Henry's posterolateral approach. Isolated weakness of extensor hallucis longus was found after operation in ten patients but not in the remainder. EMG and nerve-conduction studies confirmed injury of the nerve to extensor hallucis longus in those with weakness. We dissected 40 cadaver limbs and found that those in which the nerve to extensor hallucis longus ran close to the fibular periosteum were at risk. The injury is mostly incomplete and recovery occurs within four to six months.

Entities:  

Mesh:

Year:  2004        PMID: 15125126     DOI: 10.1302/0301-620x.86b3.14748

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  4 in total

Review 1.  Free vascularised fibular grafts in orthopaedics.

Authors:  Marko Bumbasirevic; Milan Stevanovic; Vesna Bumbasirevic; Aleksandar Lesic; Henry D E Atkinson
Journal:  Int Orthop       Date:  2014-02-22       Impact factor: 3.075

2.  An Analysis of Complications and Bone Defect Length With the Use of Induced Membrane Technique in the Upper Limb: A Systematic Review.

Authors:  Casey M O'Connor; Eric Perloff; James Drinane; Keegan Cole; Patrick G Marinello
Journal:  Hand (N Y)       Date:  2020-07-15

3.  Giant Cell Tumour Around Knee Managed by Curettage and Zoledronic Acid with Structural Support by Fibula Cortical Struts.

Authors:  V Singaravadivelu; V Kavinkumar
Journal:  Malays Orthop J       Date:  2020-11

4.  Extensor retinaculum syndrome after distal tibial fractures: anatomical basis.

Authors:  T Haumont; G C Gauchard; L Zabee; J-M Arnoux; P Journeau; P Lascombes
Journal:  Surg Radiol Anat       Date:  2007-05-15       Impact factor: 1.354

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.